v3.26.1
Note 13 - Revenue Recognition (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Sep. 30, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Disaggregation of Revenue [Line Items]        
Accrued Expense, Payor Overpayment Reimbursement, Liability   $ 1,900   $ 2,100
Contract with Customer, Performance Obligation Satisfied in Previous Period   1,000 $ 1,500  
Total revenues   124,196 149,952  
BARDA Agreement [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues $ 24,100 4,100 7,000  
Rayaldee [Member]        
Disaggregation of Revenue [Line Items]        
Contract with Customer, Liability, Revenue Recognized   6,300 6,300  
Total revenues   12,805 13,110  
Intellectual Property and Other [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues   14,000 12,300  
Increase (Decrease), Revenue from Contract with Customer, Excluding Assessed Tax   1,700    
Intellectual Property and Other [Member] | BARDA Agreement [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues   4,100 7,000  
Royalty [Member] | NGENLA        
Disaggregation of Revenue [Line Items]        
Total revenues     4,500  
Increase from gross profit   6,400    
Royalty [Member] | Eli Lilly and Regeneron        
Disaggregation of Revenue [Line Items]        
Total revenues     2,300  
Transfer of Intellectual Property and Other [Member]        
Disaggregation of Revenue [Line Items]        
Total revenues   $ 13,968 $ 12,266